GSTM2 and neuropathy: Pharmacogenomics studies suggested that patients with polymorphisms in the Glutathione S-transferases genes (GSTM) were more likely to develop severe neuropathy during oxaliplatin treatment due to decreased drug detoxification (Cavaletti et al., 2011).